vornorexant vornorexant vornorexant, also known by its developmental code names orn-0829 and ts-142, is an orexin antagonist medication which is under development for the treatment of insomnia and sleep apnea. it is a dual orexin ox1 and ox2 receptor antagonist (dora). the medication is taken by mouth. as of june 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea. it is under development by taisho pharmaceutical. vornorexantclinical dataother namesorn-0829; ts-142routes ofadministrationby mouthdrug classorexin antagonistpharmacokinetic dataelimination half-life1.3–3.3 hoursidentifiers iupac name methyl]-1,3-oxazinan-3-yl]-methanone cas number2265899-49-6pubchem cid137419776chemspider61751857uniizy54bp1ck3chemical and physical dataformulac23h22fn7o2molar mass447.474 g·mol−13d model (jsmol)interactive image smiles cc1=cc(=c(c=c1)n2n=cc=n2)c(=o)n3ccco3cn4c=cc(=n4)c5=nc=c(c=c5)f inchi inchi=1s/c23h22fn7o2/c1-16-3-6-21(31-26-8-9-27-31)18(13-16)23(32)30-10-2-12-33-22(30)15-29-11-7-20(28-29)19-5-4-17(24)14-25-19/h3-9,11,13-14,22h,2,10,12,15h2,1h3/t22-/m0/s1key:aezzjxjijfsuem-qfipxvfzsa-n vornorexant has a time to peak of 2.5 hours and a relatively short elimination half-life of 1.3 to 3.3 hours. it was designed to have a short half-life and duration in order to reduce next-day side effects like somnolence.